{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047871","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.416456+00:00","generated_at":"2026-05-21T14:51:25.984169+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Annovis Bio starts Phase 3 Alzheimer's trial, reports Q1 net loss $0.32 per share, cash $22.2M","bullets":["First participants entered pivotal Phase 3 AD trial on Feb 5, 2025; planning 760 participants, evaluating buntanetap.","Cash and equivalents $22.2M as of Mar 31, 2025 (vs $10.6M a year ago).","R&D expenses $5.0M in Q1 2025 vs $6.5M Q1 2024; G&A flat at $1.3M.","Net loss per share $0.32 basic/diluted for Q1 2025 vs $0.10 basic and $0.72 diluted in Q1 2024.","Appointed Andrew Walsh (VP Finance) as Principal Financial Officer; salary $264,000 + 25% target bonus."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047871","json":"https://secwatch.observer/filing/0001104659-25-047871.json","markdown":"https://secwatch.observer/filing/0001104659-25-047871.md","text":"https://secwatch.observer/filing/0001104659-25-047871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/0001104659-25-047871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/tm2514854d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T14:51:25.984169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9c6bd4fd0","claim":"Andrew Walsh was appointed as Principal Financial Officer at Annovis Bio, Inc..","evidence_excerpt":"On May 9, 2025, the Board of Directors appointed Andrew Walsh, the Company’s current Vice President of Finance, as the Company’s Principal Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/0001104659-25-047871-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}